The Centers for Medicare & Medicaid Services late today announced final changes to the Medicare Advantage and Part D prescription drug programs for calendar year 2017, which will increase payment rates in aggregate by a net 0.85%. When combined with expected growth in plan risk scores, CMS anticipates the MA plans and Part D sponsors will see an average revenue increase of 3.05%. In addition, CMS finalized several notable policy changes, including modifications to the risk-adjustment model to more closely align reimbursement with costs for dually eligible beneficiaries and refinements to a subset of the Star Ratings program measures to account for beneficiary socioeconomic and disability status. CMS also made slight modifications to other policies, including a slower transition to the use of encounter data in calculating risk scores, a change for which AHA advocated. AHA members will receive a Special Bulletin tomorrow with further details.

Related News Articles

Headline
Baxter Healthcare Corp., in coordination with the Food and Drug Administration, has agreed to temporarily import certain intravenous drug products, such…
Headline
President Trump yesterday named Eric Hargan as Acting Secretary of Health and Human Services. Confirmed as HHS deputy secretary last week, Hargan previously…
Headline
Hospitals generally support the proposed cancellation of the cardiac and Surgical Hip and Femur Fracture Treatment bundling program and Comprehensive Care for…
Headline
Twenty-three organizations, including the AHA, Friday urged the Centers for Medicare & Medicaid Services to suspend implementation of new draft Medicare…
Headline
The Centers for Medicare & Medicaid Services has identified the first clinicians eligible to participate in 2018 advanced alternative payment models, based…
Headline
The U.S. Senate this week voted 57-38 to confirm as Health and Human Services Deputy Secretary Eric Hargan, an attorney and shareholder in the health care…